News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,063 Results
Type
Article (19767)
Company Profile (128)
Press Release (310168)
Section
Business (105262)
Career Advice (876)
Deals (18515)
Drug Delivery (93)
Drug Development (50696)
Employer Resources (79)
FDA (7659)
Job Trends (7727)
News (185658)
Policy (17311)
Tag
Academia (726)
Alliances (27790)
Alzheimer's disease (596)
Antibody-drug conjugate (ADC) (71)
Approvals (7641)
Artificial intelligence (105)
Bankruptcy (171)
Best Places to Work (5540)
Biosimilars (73)
Breast cancer (92)
Cancer (806)
Cardiovascular disease (78)
Career advice (708)
Cell therapy (119)
Clinical research (42197)
Collaboration (345)
Compensation (107)
COVID-19 (1084)
C-suite (92)
Data (825)
Diabetes (113)
Diagnostics (1752)
Drug pricing (100)
Earnings (38402)
Employer resources (73)
Events (48006)
Executive appointments (329)
FDA (8049)
Funding (234)
Gene therapy (107)
GLP-1 (531)
Government (1809)
Healthcare (5880)
Infectious disease (1141)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7340)
Job creations (2431)
Job search strategy (646)
Layoffs (262)
Legal (4093)
Lung cancer (126)
Manufacturing (155)
Medical device (1954)
Medtech (1957)
Mergers & acquisitions (11318)
Metabolic disorders (394)
Neuroscience (826)
NextGen: Class of 2025 (2353)
Non-profit (905)
Northern California (846)
Obesity (253)
Opinion (180)
Patents (93)
People (33160)
Pharmaceutical (73)
Phase I (13196)
Phase II (17853)
Phase III (14350)
Pipeline (394)
Policy (82)
Postmarket research (1618)
Preclinical (4597)
Radiopharmaceuticals (158)
Rare diseases (185)
Real estate (3167)
Regulatory (12295)
Research institute (816)
Resumes & cover letters (138)
Southern California (784)
Startups (2006)
United States (7800)
Vaccines (228)
Weight loss (210)
Date
Today (86)
Last 7 days (318)
Last 30 days (1319)
Last 365 days (17489)
2025 (1319)
2024 (17668)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24661)
Australia (3177)
California (1945)
Canada (904)
China (230)
Colorado (78)
Connecticut (77)
Europe (50872)
Florida (312)
Illinois (195)
Indiana (143)
Japan (81)
Maryland (287)
Massachusetts (1638)
Minnesota (108)
New Jersey (755)
New York (566)
North Carolina (412)
Northern California (846)
Ohio (69)
Pennsylvania (455)
South America (605)
Southern California (784)
Texas (256)
Washington State (171)
330,063 Results for "quva pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
QuVa Pharma Completes Acquisition of LogicStream Health Combination Creates Integrated Platform of Compounded Medications, Distribution Services, and AI-Powered Data Solutions
July 25, 2024
·
5 min read
Lone Star Bio
QuVa Pharma Expands RFID Capabilities for Its Pre-Tagged, Ready-to-Administer Injectables
QuVa Pharma, Inc. announced that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1’s open, technology independent, global standards which enable interoperability and compatibility.
June 13, 2023
·
2 min read
Lone Star Bio
QuVa Pharma Adds 2D Data Matrix Barcodes on Labeling Across Its Portfolio of Compounded Sterile Products
QuVa Pharma, Inc. announced that it is expanding its product label platform by adding 2D barcodes on all products, adhering to GS1 standards.
May 3, 2023
·
2 min read
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
Lone Star Bio
QuVa Pharma Introduces Innovative Two-Sided Labels for IV Bag Compounded Sterile Products
QuVa Pharma, Inc. announced that is has developed a two-sided single label for its product portfolio of compounded IV bags.
November 15, 2022
·
2 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 33,007
Next
